ewsba.se
Delivered 11% organic revenue growth driven by broad portfolio demand, particularly in Analytics which grew over 50% due to strong downstream demand and record SoloVPE PLUS placements.
Achieved 160 basis points of adjusted operating margin expansion through disciplined cost management, pricing execution, and favorable product mix from high-margin Analytics and filtration products.
Formed a dedicated Transformation Office to accelerate the 'Fit for Growth' journey, targeting a 30% adjusted EBITDA margin by 2030 through manufacturing footprint optimization and IT modernization.
Divested the non-core Polymem business to eliminate an operating loss and sharpen focus on core bioprocessing, despite its historical role as a pandemic-era supply contributor.
Observed a significant order pickup in March, particularly in capital equipment, signaling a potential opening of the 'capital equipment tap' as customer decision-making begins to accelerate.
The company is working to regain market momentum in China through a new partnership designed to increase local manufacturing competitiveness starting in 2027, as part of a strategy to better compete with local firms.
Attributed mid-teens growth in CDMO and emerging biotech segments to a stabilizing funding environment, though overall demand remains below historical peak levels.
Reiterated 9% to 13% organic growth guidance for 2026, noting that second-quarter organic growth is expected to be similar to the first quarter and does not require second-half acceleration to reach the midpoint of the full-year outlook.
Expects the Transformation Office initiatives to deliver at least one point of annualized margin benefit by the end of 2027, front-loading the path to long-term profitability targets.
The company anticipates a moderated outlook for ATF filtration in 2026 due to customer-specific timing dynamics, with a projected return to strong growth in 2027.
Raised full-year adjusted EPS guidance to $1.97–$2.05, reflecting strong Q1 execution and the margin-accretive impact of the Polymem divestiture.
Projects Chromatography growth of 20% plus for the full year, driven by continued global traction and 'plug-and-play' convenience of OPUS prepacked columns.
Divested Polymem operations in France for nominal proceeds, removing approximately $7 million in projected 2026 revenue but improving overall operating margins.
Identified a $5 million to $6 million non-recurring charge through 2027 associated with the establishment and execution of the Transformation Office.
Noted that gene therapy remains a headwind to new modality growth, though the segment shows healthy growth when excluding specific program-related impacts.
Maintains $785 million in cash and marketable securities as 'dry powder' for potential M&A, specifically targeting Analytics and complementary bioprocessing technologies.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management clarified that the 100 basis point benefit from the Transformation Office is incremental to normal annual operating margin expansion of 100-200 basis points.
The benefit is expected to be a run-rate impact starting late 2027, with 2026 margins primarily driven by volume and mix rather than transformation initiatives.
The 'high probability' funnel (over 50% closing chance) is at its highest level ever, significantly exceeding levels seen a year ago.
While order intake accelerated in March, management noted that revenue recognition remains dependent on customer site preparedness for large-scale onshoring projects.
The partnership is a multi-phase arrangement intended to make Repligen appear 'more local' to defeat increasing domestic competition in China.
The agreement focuses on filtration consumables and is expected to be fully operational by early 2027, serving as a first step in a broader regional expansion strategy.
Emerging biotech grew over 20% in Q1, marking the fourth consecutive quarter of growth, though it still represents less than 10% of total sales.
Management expects the recent surge in biotech funding to become a more significant tailwind from the second and third quarters of 2026 onwards as capital reaches operational spending.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.